Mandate

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Related

Vinge advises on the sale of Spring Media to Two Circles

The shareholders of Spring Media have entered into an agreement to sell the shares in Spring Media to Two Circles. Spring Media is an international sports agency operating in, among other things, production, packaging, digital strategies, and rights negotiations in the field of sports rights.
October 28, 2024

Vinge has advised Stendörren Fastigheter in connection with a directed share issue of approximately SEK 505 million

Vinge has advised the property company Stendörren Fastigheter AB (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 505 million before transaction costs.
October 25, 2024

Vinge advises Main Capital and Aunetic in connection with the acquisition of Qnister

Vinge has advised Aunetic, a leading governance software specialist, in connection with the acquisition of Qnister AB (“Qnister”). The strategic acquisition enhances Aunetic’s product portfolio and strengthens its presence in the Swedish software compliance market.
October 25, 2024